Zura Bio Limited

NASDAQ:ZURA

Biotechnology

Healthcare
$0.97 +1.93%

+$0.07 today

Market cap
$92.96M
Beta
0.03
P/E (TTM)
-5.5
EPS (TTM)
-$0.67
52W Low $1.00High $7.44

Volume 3.02M

Average 0.75M

ZURA Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Zura Bio LimitedNASDAQ: ZURA

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 32.3% from a year ago

Cash & equivalents stood at $225.59M at the end of Q1 FY2026, up 32.3% from a year earlier and up 106.2% from the prior quarter. Over 3 fiscal years it compounded at +311.8% a year.

Context

  • Cash & equivalents amounted to 98.7% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +32.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$225.59M+106.2% QoQ
Last fiscal yearDec 2025
$109.41M-38.0% YoY
Year agoMar 2025
$170.57M+32.3% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.3%——
1 year-38.0%——
3-year CAGR+311.8%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
109.41M USD
Year-over-year change
-38.0%
4-year CAGR
+250.0%

Cash & Equivalents vs competitors

How ZURA compares with its peers on the latest reported figures

  • ZURA's Mar 2026 cash & equivalents of $225.59M is the highest of the 11 companies compared; the peer median is $41.97M.
  • Its year-over-year change of +32.3% is the 5th highest of 11, against a peer median of +14.7%.
  • Cash & equivalents amounts to 98.7% of total assets for ZURA, versus a peer median of 23.6%.
ZURA Competitors Peer median
Cash & Equivalents for ZURA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ZURAZura Bio LimitedMar 2026$225.59M +32.3%+311.8%98.7%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$211.38M -2.6%-16.2%86.1%
FHTXFoghorn Therapeutics Inc.Mar 2026$88.91M +45.7%+15.7%40.0%
TNYATenaya Therapeutics, Inc.Mar 2026$80.89M +50.4%+1.8%59.9%
AARDAardvark Therapeutics, Inc. Common StockMar 2026$62.44M +135.6%+44.6%63.3%
IMRXImmuneering CorporationMar 2026$47.32M +31.9%+21.0%0.0%
SGMTSagimet Biosciences Inc.Mar 2026$36.63M -43.4%+505.2%34.0%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$34.93M -42.0%-9.8%11.1%
ASMBAssembly Biosciences, Inc.Mar 2026$31.12M +32.9%+3.7%13.2%
NAUTNautilus Biotechnology, Inc.Mar 2026$14.63M -56.0%-52.4%8.2%
PYXSPyxis Oncology, Inc.Mar 2026$7.24M -43.3%-55.9%11.3%
Peer median (excluding ZURA) $41.97M+14.7%+2.8%23.6%

Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Mar 2022
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents729.22K1.57M99.81M176.5M109.41M
Short-term Investments00000
Net Receivables00000
Inventory00000
Other Current Assets0189.3K1.04M2.25M2.9M
Total Current Assets1.15M1.78M100.84M178.74M112.31M
Property, Plant & Equipment (Net)00091K126K
Goodwill00000
Intangible Assets00000
Long-term Investments139.4M0000
Tax Assets00000
Other Non-current Assets03.49M0698K1.51M
Total Non-current Assets139.4M3.49M0789K1.64M
Total Assets140.55M5.26M100.84M179.53M113.95M
Account Payables02.01M2.75M733K1.28M
Short-term Debt07.76M000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities272.29K2.78M1.2M18.78M3.32M
Total Current Liabilities272.29K14.82M20.3M19.51M12.41M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities10.08M12.5M990K00
Total Non-current Liabilities10.08M12.5M990K00
Total Liabilities10.35M27.32M21.29M19.51M12.41M
Common Stock139.38M04K7K7K
Retained Earnings(9.18M)(32.06M)(103.49M)(155.9M)(224.55M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest010M20.22M13.2M0
Total Equity130.2M(22.06M)79.55M160.02M101.54M
Total Debt07.76M000
Net Debt(729.22K)6.19M(99.81M)(176.5M)(109.41M)

Zura Bio Limited

NASDAQ:ZURA

Intrinsic Alpha fair value

Locked

Current Price

$0.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.